PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

Nov 30th 2012, 06:00

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven UpdateSummaryGlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inh

Original Post PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update source Researchmoz Market Research

Milan Tomic

Hi. I’m Designer of Blog Magic. I’m CEO/Founder of ThemeXpose. I’m Creative Art Director, Web Designer, UI/UX Designer, Interaction Designer, Industrial Designer, Web Developer, Business Enthusiast, StartUp Enthusiast, Speaker, Writer and Photographer. Inspired to make things looks better.